Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held in a virtual-only setting.
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.
Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and appointed KPMG LLP as the Company’s auditors for the current fiscal year. All candidates proposed for the position of director were elected in the following proportion:
| FOR | % FOR | ABSTENTION | % ABSTENTION | |||||
| Joseph Arena | 22,405,047 | 93.09 | % | 1,663,754 | 6.91 | % | ||
| Frank Holler | 21,008,601 | 87.29 | % | 3,060,200 | 12.71 | % | ||
| Paul Lévesque | 20,966,427 | 87.11 | % | 3,102,374 | 12.89 | % | ||
| Andrew Molson | 21,067,050 | 87.53 | % | 3,001,751 | 12.47 | % | ||
| Dawn Svoronos | 20,964,213 | 87.10 | % | 3,104,588 | 2.90 | % | ||
| Elina Tea | 21,734,254 | 90.30 | % | 2,334,547 | 9.70 | % | ||
| Dale Weil | 21,009,681 | 87.29 | % | 3,059,120 | 12.71 | % | ||
| Jordan Zwick | 23,107,383 | 96.01 | % | 961,418 | 3.99 | % | ||
Frank Holler will now act as Chair of the Board of Directors of the Company.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company’s website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
pdubuc@theratech.com
1-438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
1-514-336-7800
